摘要: |
[摘要] 目的 评价R-CHOP治疗EB病毒(Epstein-Barr virus,EBV)感染弥漫大B细胞淋巴瘤预后的影响。方法 检索了PUBMED(1994-04~2017-04)、CNKI(1994-04~2017-04)、Cochrane library(1994-04~2017-04)、WanFang Data(1996-12~2017-04)公开发表的关于R-CHOP治疗EBV阳性弥漫大B细胞淋巴瘤的相关研究文献,按照Cochrane质量评价系统评价纳入研究质量后,应用RevMan 5.0软件进行Meta分析。结果 共纳入7篇队列研究,其中EBV阳性弥漫大B细胞淋巴瘤140例,EBV阴性弥漫大B细胞淋巴瘤1 812例。Meta分析结果显示,EBV阳性弥漫大B细胞淋巴瘤组的总生存期(HR=3.24,95%CI=1.88~5.58,P<0.0001)、无病生存期(HR=1.83,95%CI=1.44~3.25,P=0.0002)均差于EBV阴性弥漫大B细胞淋巴瘤组。结论 在以美罗华治疗弥漫大B细胞淋巴瘤的时代,EBV阳性仍是患者的主要不良预后因素。R-CHOP治疗EBV阳性弥漫大B细胞淋巴瘤的疗效欠佳。EBV可能参与了弥漫大B细胞淋巴瘤的发生、发展的全过程。 |
关键词: 弥漫大B细胞淋巴瘤 R-CHOP EB病毒 Meta分析 |
DOI:10.3969/j.issn.1674-3806.2018.09.10 |
分类号:R 733 |
基金项目: |
|
Meta-analysis of the effect of EBV on diffuse large B-cell lymphoma treated with R-CHOP |
WEI Hua-ping
|
Department of Oncology, Beijing Huairou Hospital, Beijing 101400, China
|
Abstract: |
[Abstract] Objective To evaluate the effect of EB virus(EBV) on diffuse large B-cell lymphoma(DLBCL) treated with R-CHOP chemotherapy. Methods The domestic and abroad authoritative databases were retrieved to find the published literature of R-CHOP chemotherapy for EBV positive DLBCL in PUBMED (1994-04 ~ 2017-04), CNKI (1994-04~2017-04), Cochrane library(1994-04~2017-04) and WanFang Data(1996-12~2017-04). The quality of the included studies was assessed by the Cochrane system method and Meta-analysis was performed using RevMan 5.0 software. Results Seven randomized controlled trials involving 140 EBV-positive patients and 1812 EBV-negative patients were included. Meta-analysis indicated that EBV-positive group was worse than EBV-negative group in overall survival(HR=3.24, 95%CI=1.88~5.58, P<0.0001) and progression-survival(HR=1.83, 95%CI=1.44~3.25, P=0.0002). Conclusion In the era of R-CHOP chemotherapy for DLBCL, EBV-positive is still the main adverse prognostic factor. The efficacy of R-CHOP chemotherapy for DLBCL is still uncertain, and EBV may involve in the occurrence and development of DLBCL. |
Key words: Diffuse large B-cell lymphoma(DLBCL) R-CHOP Epstein-Barr virus Meta-analysis |